Scarica l'app Stockscreener
55.03
0.36%
-0.20
Dopo l'orario di chiusura:
55.03
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$55.23
Aprire:
$55.25
Volume 24 ore:
615.60K
Relative Volume:
0.82
Capitalizzazione di mercato:
$2.65B
Reddito:
$1.36B
Utile/perdita netta:
$123.81M
Rapporto P/E:
22.83
EPS:
2.41
Flusso di cassa netto:
$20.35M
1 W Prestazione:
+1.07%
1M Prestazione:
-26.82%
6M Prestazione:
-14.77%
1 anno Prestazione:
-28.24%
Intervallo 1D:
$54.59
$55.71
Intervallo di 1 settimana:
$53.50
$56.64
Portata 52W:
$50.68
$94.98
Haemonetics Corp Stock (HAE) Company Profile
Nome
Haemonetics Corp
Settore
Industria
Telefono
(781) 848-7100
Indirizzo
125 SUMMER STREET, BOSTON, MA
Confronta HAE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HAE
Haemonetics Corp
|
55.03 | 2.66B | 1.36B | 123.81M | 20.35M | 2.41 |
|
ABT
Abbott Laboratories
|
131.46 | 229.03B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
105.87 | 157.64B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
393.15 | 150.76B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.05 | 118.26B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
80.90 | 47.71B | 5.69B | 1.41B | 577.90M | 6.95 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-11 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2025-08-08 | Reiterato | Barrington Research | Outperform |
| 2025-08-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-07-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-06-26 | Iniziato | Robert W. Baird | Outperform |
| 2025-02-07 | Downgrade | BofA Securities | Neutral → Underperform |
| 2024-12-06 | Iniziato | JP Morgan | Overweight |
| 2024-11-08 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-09-13 | Iniziato | CL King | Buy |
| 2024-09-11 | Iniziato | BofA Securities | Neutral |
| 2024-09-10 | Iniziato | BTIG Research | Buy |
| 2024-06-12 | Aggiornamento | Needham | Hold → Buy |
| 2022-10-13 | Iniziato | Mizuho | Buy |
| 2022-01-27 | Downgrade | Needham | Buy → Hold |
| 2021-12-15 | Downgrade | Citigroup | Buy → Neutral |
| 2021-08-17 | Ripresa | Raymond James | Outperform |
| 2021-06-17 | Iniziato | Citigroup | Buy |
| 2021-05-14 | Aggiornamento | CJS Securities | Market Perform → Market Outperform |
| 2021-04-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| 2021-02-03 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2021-01-21 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2020-11-05 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2020-05-06 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2020-03-31 | Aggiornamento | CJS Securities | Market Perform → Market Outperform |
| 2020-01-10 | Iniziato | Needham | Buy |
| 2019-08-07 | Reiterato | Barrington Research | Outperform |
| 2019-05-14 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2019-05-08 | Reiterato | Barrington Research | Outperform |
| 2018-08-09 | Reiterato | Barrington Research | Outperform |
| 2018-02-07 | Reiterato | Barrington Research | Outperform |
| 2018-01-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-11-08 | Reiterato | Barrington Research | Outperform |
| 2017-08-08 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2017-07-13 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2017-02-07 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2016-11-08 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2016-11-07 | Reiterato | The Benchmark Company | Hold |
| 2016-09-20 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| 2016-08-15 | Downgrade | Sidoti | Buy → Neutral |
| 2016-08-02 | Reiterato | Jefferies | Buy |
| 2016-08-02 | Reiterato | The Benchmark Company | Hold |
Mostra tutto
Haemonetics Corp Borsa (HAE) Ultime notizie
Analyzing Haemonetics Corporation with multi timeframe chartsJuly 2025 Levels & Weekly High Conviction Ideas - Newser
Can machine learning forecast Haemonetics Corporation recovery2025 Winners & Losers & Technical Pattern Based Buy Signals - Newser
Analyzing net buyer seller activity in Haemonetics Corporation2025 Support & Resistance & Long-Term Safe Return Strategies - Newser
What moving averages say about Haemonetics CorporationVolume Spike & Verified Chart Pattern Signals - Newser
Leading vs lagging indicators on Haemonetics Corporation performanceTrade Risk Summary & Consistent Return Strategy Ideas - Newser
Is Haemonetics Corporation stock ready for a breakoutChart Signals & Reliable Entry Point Alerts - Newser
What candlestick patterns are forming on Haemonetics CorporationFed Meeting & Technical Confirmation Alerts - Newser
Can a trend reversal in Haemonetics Corporation lead to recoveryCEO Change & Verified Technical Signals - Newser
Can Haemonetics Corporation hit a new high this month2025 Market Outlook & Smart Money Movement Tracker - Newser
Building trade automation scripts for Haemonetics CorporationTrade Volume Report & Low Risk Growth Stock Ideas - Newser
Advanced analytics toolkit walkthrough for Haemonetics CorporationWeekly Investment Summary & Fast Entry High Yield Stock Tips - Newser
Is Haemonetics Corporation a top pick in the sectorTrade Entry Report & Community Trade Idea Sharing Platform - theviewers.co.kr
Published on: 2025-08-23 17:00:15 - Newser
Mizuho Reduces PT on Haemonetics Corporation (HAE) Following Fiscal Q1 2025 Results - Insider Monkey
Quantitative breakdown of Haemonetics Corporation recent move2025 Analyst Calls & Momentum Based Trading Signals - Newser
MACD Cross Could Confirm Trend in Haemonetics Corporation2025 Dividend Review & Growth Focused Entry Point Reports - kangso.co.kr
Is Haemonetics Corporation meeting your algorithmic filter criteria2025 Breakouts & Breakdowns & Technical Confirmation Alerts - Newser
Full technical analysis of Haemonetics Corporation stockEarnings Miss & Fast Gain Stock Trading Tips - Newser
Technical Charts Suggest Momentum Shift in Haemonetics CorporationWeekly Risk Summary & Low Risk High Reward Ideas - 더경남뉴스
How to escape a deep drawdown in Haemonetics CorporationMarket Performance Report & Verified Short-Term Plans - Newser
Vanguard Group Inc. Has $324.08 Million Stake in Haemonetics Corporation $HAE - Defense World
Should you hold or exit Haemonetics Corporation nowQuarterly Market Review & Risk Managed Investment Strategies - Newser
What makes Haemonetics Corporation stock attractive to long term investorsFed Meeting & Daily Oversold Bounce Ideas - Newser
PNC Financial Services Group Inc. Has $294,000 Stock Holdings in Haemonetics Corporation (NYSE:HAE) - Defense World
Will Haemonetics Corporation see short term momentum2025 Major Catalysts & Reliable Entry Point Trade Alerts - Newser
Is Haemonetics Corporation stock entering bullish territory2025 Technical Overview & Stepwise Swing Trade Plans - Newser
Haemonetics Corporation stock outlook for YEAR2025 Retail Activity & High Yield Stock Recommendations - Newser
Patient Blood Management Market Growth Analysis Report 2025-2033 | AI-Driven Analytics Revolutionize Blood Management Strategies, Blockchain Enhances Supply Transparency and Safety - GlobeNewswire Inc.
Mizuho lowers Haemonetics stock price target to $70 on VASCADE MVP slowdown - Investing.com Nigeria
The Top 5 Analyst Questions From Haemonetics’s Q2 Earnings Call - Yahoo Finance
Haemonetics Corporation Shows Support at Fibonacci Level2025 Buyback Activity & Fast Entry High Yield Tips - metal.it
Haemonetics (NYSE:HAE) Rating Lowered to Outperform at Raymond James Financial - Defense World
Haemonetics Corporation (NYSE:HAE) Q1 2026 Earnings Call Transcript - Insider Monkey
I’m Recommending Haemonetics Again, But With Caveats (Ratings Upgrade) (NYSE:HAE) - Seeking Alpha
Haemonetics Corporation shares fall 2.69% intraday after Raymond James downgrades to Outperform. - AInvest
Understanding Haemonetics (HAE) Reliance on International Revenue - Yahoo Finance
Haemonetics stock rating downgraded by Raymond James on vascular closure slowdown - Investing.com
Haemonetics’ (HAE) “Neutral” Rating Reiterated at JPMorgan Chase & Co. - Defense World
Mizuho Issues Pessimistic Forecast for Haemonetics (NYSE:HAE) Stock Price - Defense World
Haemonetics Corp Azioni (HAE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.76%
0.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):